Evidence map›Paper›PMID 39611928›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2024

Bioinformatics Examination of Glioblastoma Identifies a Potential Panel of Therapeutic Biomarkers.

Fatemeh Bandarian, Farideh Razi, Zahra Razzaghi, Mohammad Rostami-Nejad, Babak Arjmand, Alireza Ahmadzadeh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Journal of translational medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fatemeh BandarianEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Farideh RaziDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Zahra RazzaghiLaser application in medical sciences research center, Shahid Beheshti University of medical sciences, Tehran, Iran.
Mohammad Rostami-NejadCeliac Disease and Gluten Related Disorders Research Center, Research Institute for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-2495-1831
Babak ArjmandCell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Alireza AhmadzadehProteomics Research Center, System Biology Institute, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-5474-6997

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveGlioblastoma, previously recognized as glioblastoma multiform (GBM), is the most aggressive and most common type of cancer that originates in the brain and has a very poor prognosis for survival. Glioblastoma, as one of the lethal cancers of the brain, is important to be studied in terms of molecular exploration.

methodsBioinformatics approaches could be a promising complementary study for identifying more robust biomarkers. This study evaluates the gene expression profile of normal brain endothelial cells versus glioblastoma tumor cells with positive CD3 in more depth by applying R Studio and Cytoscape and its plug-ins.

resultsA network of differentially expressed genes (DEGs) introduced promising candidates comprised of TP53, EGFR, FN1, JUN, and CDC42 and their related biological processes. Comprised of differentially expressed genes, this panel's dysregulation could significantly affect the stability of the protein-protein interaction (PPI) network. Moreover, previous studies have validated these genes' relevance to this cancer type.

conclusionIn conclusion, the molecular profile of glioblastoma aids in drug targeting following thorough validation assessments. Five key genes and their related biological processes are possible  drug targets to control glioblastoma.

Indexed as

Biomarkers, TumorBrain NeoplasmsComputational BiologyGlioblastomacdc42 GTP-Binding ProteinErbB ReceptorsFibronectinsGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPrognosisProtein Interaction MapsTumor Suppressor Protein p53Biomarkers, Tumorcdc42 GTP-Binding ProteinCDC42 protein, humanEGFR protein, humanErbB ReceptorsFibronectinsFN1 protein, humanTP53 protein, humanTumor Suppressor Protein p53Biomarker panelEndothelial cellsGene expressionglioblastoma (GBM)

Identifiers

PMID39611928
PMCPMC11996113

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.